Agents that hinder platelet functions, including aspirin, ADP receptor antagonists (e.g., ticagrelor and clopidogrel), thrombin receptor-targeting molecules, inhibitors of GP Ib-IX, P-selectin, and CLEC-2, can be used as complementary therapeutics in ovarian cancer. This evidence concerns the gene CLEC1B and ovarian carcinoma.